According to the company, the board will support the advancement of late-stage ophthalmic assets Nyxol and APX3330.
Ocuphire Pharma Inc. today announced that it has appointed 6 new key opinion leaders (KOLs) across retina, refractive surgery, and optometry to its medical advisory board (MAB).
According to Mina Sooch, founder and CEO of Ocuphire Pharma, the opportunity to assemble a roster of respected medical advisors will broaden Ocuphire’s potential.
“In the medical community, their clinical expertise and knowledge of ophthalmic drug development have earned them global distinction as key thought-leaders, panelists, authors, clinical investigators, and commercial launch experts in the field of ophthalmology,” Sooch said in a statement. “We look forward to their invaluable contributions and insights as we advance our lead clinical assets, Nyxol and APX3330 in reversal of mydriasis, presbyopia, night vision disturbance, and diabetic eye diseases.”
Jay Pepose, MD, PhD, a member of Ocuphire’s Board of Directors and MAB noted that the company is fortunate to have a chance to expand its roster of KOLs.
“Over the last three years, our thirteen-member MAB has been vital in the design of our well-executed clinical trials, participating in regulatory interactions, and advancing discussions with global ophthalmic strategic partners,” he said in a statement.
Moreover, Pepose noted that the MAB has played an important role in presenting Nyxol and APX3330 to the medical community through peer-reviewed publications and industry conferences.
“The addition of these six world-class individuals, many of whom I have had the privilege of working with over several decades, will help to advance Ocuphire’s portfolio of innovative drug candidates to address unmet medical needs of our patients,” he said in the statement.
The new members of the Medical Advisory Board include: